Lofepramine/phenylalanine - MultiCell Technologies

Drug Profile

Lofepramine/phenylalanine - MultiCell Technologies

Alternative Names: L-phenylalanine/Lofepramine; LAX-202; Lofepramine/L-phenylalanine; MCT-125; Phenylalanine/lofepramine

Latest Information Update: 03 Sep 2015

Price : $50

At a glance

  • Originator Unknown
  • Class Dibenzazepines; Essential amino acids; Neuropsychotherapeutics; Tricyclic antidepressants
  • Mechanism of Action Adrenergic uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Fatigue

Most Recent Events

  • 03 Sep 2015 Lofepramine/phenylalanine is still in phase-II development for Fatigue
  • 02 Nov 2010 MultiCell receives Qualifying Therapeutic Discovery Project grant under the Patient Protection and Affordable Care Act of 2010 (PPACA) for MCT 125 development in Fatigue
  • 03 Jan 2006 Data from a media release have been added to the Neurological Disorders therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top